Consultation outcome

Consultation on Acnecide face gel and face wash

• From: Medicines and Healthcare products Regulatory Agency
• Published: 9 May 2019
• Last updated: 23 September 2019 — See all updates

This consultation has concluded

Read the full outcome

Acnecide public assessment report

PDF, 237 KB, 14 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail of outcome

The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Acnecide Face Gel and Acnecide Face Wash from pharmacy (P) to general sale list (GSL) medicines for the treatment of mild acne affecting the face in adults and adolescents aged 12 years and over. See the public assessment report above for more information.

Feedback received

Acnecide patient response

PDF, 41.1 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Acnecide patient response

PDF, 264 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Acnecide patient response

PDF, 255 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Acnecide individual/member of the public response

PDF, 122 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Acnecide RPS response

PDF, 84.9 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Acnecide NPA response

PDF, 93.2 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Acnecide CPS response

PDF, 94.5 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Acnecide RAC response

PDF, 607 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail of feedback received

Consultation ARM 98 which summarises the proposal for pharmacy (P) to general sale list (P to GSL) reclassification of Acnecide Face Gel and Acnecide Face Wash was posted on the GOV.UK website on 9 May 2019. The deadline for comments was given as 30 May 2019.

Eight responses were received. Four responses (from patients/members of the public) were in favour of the reclassification. Four responses (two from professional bodies/associations representing pharmacists, one from a pharmacy trade body and one from a pharmaceutical company regulatory affairs consultant) were not in favour.

• Patient
• Patient
• Patient
• Individual/member of the public
• Royal Pharmaceutical Society (RPS)
• National Pharmacy Association (NPA)
• Community Pharmacy Scotland (CSP)
• Regulatory Affairs Consultant (RAC)

---

Original consultation

Summary

We are seeking views on a proposal to make Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel available from general sales outlets.

This consultation ran from
9:30am on 9 May 2019 to 5pm on 30 May 2019

Consultation description

We are proposing to make Acnecide ‘Face’ products available from general sales outlets with more limited conditions of use than the current pharmacy products.

The products are Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel. They are preparations (face gel and face wash) containing benzoyl peroxide intended for use on the face.

They are for the treatment of mild acne affecting the face in adults and adolescents aged 12 years and over.

The Commission on Human Medicines (CHM) has advised that Acnecide `Face’ products can be available as General Sale List (GSL) medicines.

This deadline for comments was 5:00pm on 30 May 2019.

Documents

Acnecide public consultation: proposal to make available from general sales outlets

PDF, 1.28 MB, 31 pages

Published 9 May 2019
Last updated 23 September 2019 + show all updates

1. 23 September 2019

   Uploaded public assessment report (PAR) and updated final outsome/summary text of consultation.

2. 9 May 2019

   First published.